THELMA

orange__line

Phase I Multicenter Clinical Trial Evaluating the Combination of Trastuzumab Emtansine (T-DM1) and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer.

The primary goal is to determine the maximum tolerated dose (MTD) of the combination of T-DM1 and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously treated with taxanes and trastuzumab-based therapy.

In addition, pharmacokinetic data on the combination of T-DM1 and lyposomal doxorubicin will be obtained.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
THELMA
Breast T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer I ~24 5 Spain, France Actively enrolling patients

SABCS 2016 Download the abstract

Botón CONTACT US